BioCentury | May 21, 2020
Product Development

Translate Bio brings chronic disease-scale manufacturing to COVID-19 mRNA vaccine

...the spike protein. Other companies that have disclosed preclinical mRNA vaccine programs for COVID-19 include Capricor...
BioCentury | May 1, 2020
Product Development

April 30 Quick Takes: Pfizer to co-develop Valneva’s Lyme disease vaccine; plus Aravive-WuXi Biologics, Siga-BARDA, Pear, Capricor

...ARDS, the evasins could stop cytokine storms. Capricor gains on COVID-19 cell therapy compassionate use Capricor...
...Four patients that received the allogeneic cardiac cell therapy have been discharged. FDA has cleared Capricor...
...TPOXX, oral tecovirimat (oral ST-246, oral Arestvyr, SIGA-246) reSET reSET-O CAP-1002 Valneva SE Pfizer Inc. Aravive Inc. WuXi Biologics Inc. Siga Technologies Inc. Pear Therapeutics Capricor...
BioCentury | Apr 4, 2020
Product Development

COVID-19 roundup: FDA’s expanded access program for convalescent plasma; plus more funding from BARDA, tests from Eurofins, BD-BioGx, and more

...and Clover Biopharmaceuticals (see “GSK to Provide Adjuvant” ). Capricor, Revive redirect candidates to COVID-19 Capricor...
...plc Emergent BioSolutions Inc. SAB Biotherapeutics Inc. Biotechnology Innovation Organization XBiotech Inc. U.S. Department of Defense Eurofins Scientific S.E. Becton Dickinson and Co. Capricor...
BioCentury | Jul 16, 2019
Clinical News

July 15 Clinical Quick Takes: Zejula meets in Phase III for 1L ovarian cancer; plus Capricor, Avrobio and NIH

...from PRIMA at an upcoming scientific meeting. Capricor climbs on interim Phase II DMD data Capricor...
...Mary Romeo, Assistant Editor Ad26.Mos4.HIV AVR-RD-01, avr-02 CAP-1002 Zejula (Brand), ZL-2306 (Compound #), MK-4827 (Compound #), niraparib (Generic), Zejula (Informal) Avrobio Capricor...
BioCentury | Feb 8, 2019
Clinical News

Capricor resumes DMD trial, will seek funding

...to investigate a severe allergic reaction that occurred in a patient during CAP-1002 infusion (see "Capricor...
...reactions. Further enrollment in the trial will not begin until the company secures additional funding. Capricor...
...Sept. 30, 2018, Capricor had $4.4 million in cash. CAP-1002 comprises allogeneic cardiosphere-derived stem cells. Capricor...
BioCentury | Jan 4, 2019
Clinical News

Capricor places DMD trial on hold

...DMD) to investigate a severe allergic reaction that occurred in a patient during CAP-1002 infusion. Capricor...
...of Performance of the Upper Limb at month 12. CAP-1002 comprises allogeneic cardiosphere-derived stem cells. Capricor...
...thickening at months six and 12, and safety Status: Phase II clinical hold Milestone: NA Meghan Sullivan CAP-1002 Capricor...
BioCentury | Jan 19, 2018
Company News

Capricor and Cedars-Sinai expand cardiosphere deal

...Cedars-Sinai Medical Center (Los Angeles, Calif.) granted cardiovascular company Capricor Therapeutics Inc. (NASDAQ:CAPR) exclusive, worldwide rights...
...by adding seven new patent applications to a 2014 partnership. The new patent applications extend Capricor's...
...Capricor Therapeutics Inc. (NASDAQ:CAPR), Beverly Hills, Calif. Cedars-Sinai Medical Center, Los Angeles, Calif. Business: Cardiovascular Allison Johnson CAP-1002 CAP-2003 Capricor...
BioCentury | Nov 9, 2017
Targets & Mechanisms

Vesicular fuel

...included in the figure are as follows (clockwise from lower right): Exovita Biosciences Inc. , Capricor...
BioCentury | Jul 28, 2017
Clinical News

FDA to allow limb function endpoint in Capricor's DMD trials

...that "a number" of upper limb extremity function measures for older, non-ambulatory patients already exist. Capricor...
...cells designed to release exosomes that are immunomodulatory and exert anti-inflammatory, anti-fibrotic and anti-apoptotic effects. Capricor...
...use data from the trial, expected in 2H19, to support an NDA submission. Jaime De Leon AVI-4658 CAP-1002 deflazacort Emflaza eteplirsen Exondys 51 idebenone MP-104 Raxone SNT-MC17 Capricor...
BioCentury | Jul 28, 2017
Clinical News

FDA to allow limb function endpoint in Capricor's DMD trials

...that "a number" of upper limb extremity function measures for older, non-ambulatory patients already exist. Capricor...
...cells designed to release exosomes that are immunomodulatory and exert anti-inflammatory, anti-fibrotic and anti-apoptotic effects. Capricor...
...to treat DMD. Capricor Therapeutics Inc. (NASDAQ:CAPR), Beverly Hills, Calif. Product: CAP-1002 Business: Musculoskeletal Jaime De Leon CAP-1002 Capricor...
Items per page:
1 - 10 of 54
BioCentury | May 21, 2020
Product Development

Translate Bio brings chronic disease-scale manufacturing to COVID-19 mRNA vaccine

...the spike protein. Other companies that have disclosed preclinical mRNA vaccine programs for COVID-19 include Capricor...
BioCentury | May 1, 2020
Product Development

April 30 Quick Takes: Pfizer to co-develop Valneva’s Lyme disease vaccine; plus Aravive-WuXi Biologics, Siga-BARDA, Pear, Capricor

...ARDS, the evasins could stop cytokine storms. Capricor gains on COVID-19 cell therapy compassionate use Capricor...
...Four patients that received the allogeneic cardiac cell therapy have been discharged. FDA has cleared Capricor...
...TPOXX, oral tecovirimat (oral ST-246, oral Arestvyr, SIGA-246) reSET reSET-O CAP-1002 Valneva SE Pfizer Inc. Aravive Inc. WuXi Biologics Inc. Siga Technologies Inc. Pear Therapeutics Capricor...
BioCentury | Apr 4, 2020
Product Development

COVID-19 roundup: FDA’s expanded access program for convalescent plasma; plus more funding from BARDA, tests from Eurofins, BD-BioGx, and more

...and Clover Biopharmaceuticals (see “GSK to Provide Adjuvant” ). Capricor, Revive redirect candidates to COVID-19 Capricor...
...plc Emergent BioSolutions Inc. SAB Biotherapeutics Inc. Biotechnology Innovation Organization XBiotech Inc. U.S. Department of Defense Eurofins Scientific S.E. Becton Dickinson and Co. Capricor...
BioCentury | Jul 16, 2019
Clinical News

July 15 Clinical Quick Takes: Zejula meets in Phase III for 1L ovarian cancer; plus Capricor, Avrobio and NIH

...from PRIMA at an upcoming scientific meeting. Capricor climbs on interim Phase II DMD data Capricor...
...Mary Romeo, Assistant Editor Ad26.Mos4.HIV AVR-RD-01, avr-02 CAP-1002 Zejula (Brand), ZL-2306 (Compound #), MK-4827 (Compound #), niraparib (Generic), Zejula (Informal) Avrobio Capricor...
BioCentury | Feb 8, 2019
Clinical News

Capricor resumes DMD trial, will seek funding

...to investigate a severe allergic reaction that occurred in a patient during CAP-1002 infusion (see "Capricor...
...reactions. Further enrollment in the trial will not begin until the company secures additional funding. Capricor...
...Sept. 30, 2018, Capricor had $4.4 million in cash. CAP-1002 comprises allogeneic cardiosphere-derived stem cells. Capricor...
BioCentury | Jan 4, 2019
Clinical News

Capricor places DMD trial on hold

...DMD) to investigate a severe allergic reaction that occurred in a patient during CAP-1002 infusion. Capricor...
...of Performance of the Upper Limb at month 12. CAP-1002 comprises allogeneic cardiosphere-derived stem cells. Capricor...
...thickening at months six and 12, and safety Status: Phase II clinical hold Milestone: NA Meghan Sullivan CAP-1002 Capricor...
BioCentury | Jan 19, 2018
Company News

Capricor and Cedars-Sinai expand cardiosphere deal

...Cedars-Sinai Medical Center (Los Angeles, Calif.) granted cardiovascular company Capricor Therapeutics Inc. (NASDAQ:CAPR) exclusive, worldwide rights...
...by adding seven new patent applications to a 2014 partnership. The new patent applications extend Capricor's...
...Capricor Therapeutics Inc. (NASDAQ:CAPR), Beverly Hills, Calif. Cedars-Sinai Medical Center, Los Angeles, Calif. Business: Cardiovascular Allison Johnson CAP-1002 CAP-2003 Capricor...
BioCentury | Nov 9, 2017
Targets & Mechanisms

Vesicular fuel

...included in the figure are as follows (clockwise from lower right): Exovita Biosciences Inc. , Capricor...
BioCentury | Jul 28, 2017
Clinical News

FDA to allow limb function endpoint in Capricor's DMD trials

...that "a number" of upper limb extremity function measures for older, non-ambulatory patients already exist. Capricor...
...cells designed to release exosomes that are immunomodulatory and exert anti-inflammatory, anti-fibrotic and anti-apoptotic effects. Capricor...
...use data from the trial, expected in 2H19, to support an NDA submission. Jaime De Leon AVI-4658 CAP-1002 deflazacort Emflaza eteplirsen Exondys 51 idebenone MP-104 Raxone SNT-MC17 Capricor...
BioCentury | Jul 28, 2017
Clinical News

FDA to allow limb function endpoint in Capricor's DMD trials

...that "a number" of upper limb extremity function measures for older, non-ambulatory patients already exist. Capricor...
...cells designed to release exosomes that are immunomodulatory and exert anti-inflammatory, anti-fibrotic and anti-apoptotic effects. Capricor...
...to treat DMD. Capricor Therapeutics Inc. (NASDAQ:CAPR), Beverly Hills, Calif. Product: CAP-1002 Business: Musculoskeletal Jaime De Leon CAP-1002 Capricor...
Items per page:
1 - 10 of 54